P4‐239: The role of elisa in early diagnosis of Alzheimer's disease
Annotatsiya
The aim of our study was to establish the relationship with cognitive performance level of DHEA-S with early form of Alzheimer's disease (AD). The study included 30 patients (12 men and 18 women), aged 65 (average age 61,3 ± 5,7 years) years from the presence of cognitive impairment, and 5 healthy individuals. Research was conducted by ELISA with the definition of the level of DHEA-S before and after the oxidation catalyst Fe2+. Clinic of AD in patients of the main group was characterized by the presence of organic neurological deficits and a progressive decline in cognitive function. Neuropsychological research on the MMSE results suggests cognitive functions: 21,8 ± 4,05 in the group of patients with asthma, 28,1 ± 0,8 in healthy individuals. Oxidation of serum led to a sharp increase in DHEA levels in the control group (up to 5,2 ± 0,5; after 7,1 ± 0,5), whereas in the serum of patients with AD, improving wasn't observed or was negligible (up to 2,1 ± 0,5; after 2,3 ± 0,3). Determining the level of DHEA and the reaction of Fe2+ may be taken as one of the biochemical markers of diagnosis of early forms of AD, which can be recommended for screening diagnosis of early forms of AD.